NO993396D0 - Kinolin- ig kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi - Google Patents

Kinolin- ig kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi

Info

Publication number
NO993396D0
NO993396D0 NO993396A NO993396A NO993396D0 NO 993396 D0 NO993396 D0 NO 993396D0 NO 993396 A NO993396 A NO 993396A NO 993396 A NO993396 A NO 993396A NO 993396 D0 NO993396 D0 NO 993396D0
Authority
NO
Norway
Prior art keywords
quinolinic
therapy
treatment
compounds useful
benign prostatic
Prior art date
Application number
NO993396A
Other languages
English (en)
Other versions
NO318609B1 (no
NO993396L (no
Inventor
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO993396D0 publication Critical patent/NO993396D0/no
Publication of NO993396L publication Critical patent/NO993396L/no
Publication of NO318609B1 publication Critical patent/NO318609B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19993396A 1997-01-11 1999-07-09 Kinolin- og kinazolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi NO318609B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (3)

Publication Number Publication Date
NO993396D0 true NO993396D0 (no) 1999-07-09
NO993396L NO993396L (no) 1999-07-09
NO318609B1 NO318609B1 (no) 2005-04-18

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993396A NO318609B1 (no) 1997-01-11 1999-07-09 Kinolin- og kinazolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi

Country Status (45)

Country Link
US (4) US6169093B1 (no)
EP (1) EP0968208B1 (no)
JP (1) JP3357677B2 (no)
KR (1) KR100347472B1 (no)
CN (2) CN1191249C (no)
AP (1) AP819A (no)
AR (1) AR010396A1 (no)
AT (1) ATE242238T1 (no)
AU (1) AU724990B2 (no)
BG (1) BG63918B1 (no)
BR (1) BR9807068A (no)
CA (1) CA2277473C (no)
CZ (1) CZ295580B6 (no)
DE (1) DE69815313T2 (no)
DK (1) DK0968208T3 (no)
DZ (1) DZ2394A1 (no)
EA (1) EA002851B1 (no)
ES (1) ES2198695T3 (no)
GB (1) GB9700504D0 (no)
HK (1) HK1054389B (no)
HN (1) HN1998000002A (no)
HR (1) HRP980010B1 (no)
HU (1) HUP0000942A3 (no)
ID (1) ID21863A (no)
IL (1) IL130762A (no)
IS (1) IS2012B (no)
MA (1) MA26465A1 (no)
MY (1) MY119623A (no)
NO (1) NO318609B1 (no)
NZ (1) NZ336302A (no)
OA (1) OA11074A (no)
PA (1) PA8444301A1 (no)
PE (1) PE44499A1 (no)
PL (1) PL334678A1 (no)
PT (1) PT968208E (no)
SA (1) SA97180705B1 (no)
SI (1) SI0968208T1 (no)
SK (1) SK284779B6 (no)
TN (1) TNSN98004A1 (no)
TR (1) TR199901604T2 (no)
TW (1) TW444013B (no)
UA (1) UA62945C2 (no)
WO (1) WO1998030560A1 (no)
YU (1) YU31699A (no)
ZA (1) ZA98166B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
IL150634A0 (en) * 2000-03-03 2003-02-12 Pfizer 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
EP1315714B1 (en) 2000-08-31 2005-11-09 F. Hoffmann-La Roche Ag Quinazoline derivatives as alpha-1 adrenergic antagonists
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
EP1556381B1 (en) 2002-09-26 2008-02-20 Pfizer Limited Pyrazole amides for treating hiv infections
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2530450A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
JP4185154B2 (ja) 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法。
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG11201607973XA (en) * 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
GR79603B (no) * 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CN1403453A (zh) 2003-03-19
HK1025327A1 (en) 2000-11-10
EA199900531A1 (ru) 2000-02-28
IS5093A (is) 1999-06-25
EA002851B1 (ru) 2002-10-31
PT968208E (pt) 2003-09-30
ATE242238T1 (de) 2003-06-15
CA2277473C (en) 2003-08-12
TR199901604T2 (xx) 1999-12-21
YU31699A (sh) 2001-07-10
AU6208898A (en) 1998-08-03
US20020040028A1 (en) 2002-04-04
EP0968208A1 (en) 2000-01-05
OA11074A (en) 2002-03-13
BG63918B1 (bg) 2003-06-30
CZ9902436A3 (cs) 2000-10-11
AR010396A1 (es) 2000-06-07
MY119623A (en) 2005-06-30
SK284779B6 (sk) 2005-11-03
SI0968208T1 (en) 2003-10-31
BR9807068A (pt) 2000-05-02
BG103560A (en) 2000-06-30
IL130762A (en) 2005-12-18
AP9801175A0 (en) 1998-01-31
IS2012B (is) 2005-05-13
JP2000507966A (ja) 2000-06-27
HK1054389B (zh) 2005-10-14
EP0968208B1 (en) 2003-06-04
WO1998030560A1 (en) 1998-07-16
KR100347472B1 (ko) 2002-08-07
KR20000070022A (ko) 2000-11-25
PA8444301A1 (es) 2000-05-24
SK90799A3 (en) 2001-03-12
HRP980010A2 (en) 1998-10-31
DZ2394A1 (fr) 2003-06-04
CN1191249C (zh) 2005-03-02
UA62945C2 (en) 2004-01-15
US6521629B2 (en) 2003-02-18
CN1243513A (zh) 2000-02-02
DE69815313T2 (de) 2003-12-11
DE69815313D1 (de) 2003-07-10
PL334678A1 (en) 2000-03-13
AP819A (en) 2000-04-03
TW444013B (en) 2001-07-01
JP3357677B2 (ja) 2002-12-16
MA26465A1 (fr) 2004-12-20
HK1054389A1 (en) 2003-11-28
HN1998000002A (es) 1999-01-08
HRP980010B1 (en) 2002-06-30
TNSN98004A1 (fr) 2005-03-15
HUP0000942A3 (en) 2002-06-28
SA97180705B1 (ar) 2005-12-26
US20030130259A1 (en) 2003-07-10
CA2277473A1 (en) 1998-07-16
CN1093858C (zh) 2002-11-06
ID21863A (id) 1999-08-05
NO318609B1 (no) 2005-04-18
IL130762A0 (en) 2001-01-28
DK0968208T3 (da) 2003-07-28
CZ295580B6 (cs) 2005-08-17
ZA98166B (en) 1999-07-09
US6169093B1 (en) 2001-01-02
NZ336302A (en) 2000-08-25
ES2198695T3 (es) 2004-02-01
US6653302B2 (en) 2003-11-25
HUP0000942A2 (hu) 2001-04-28
NO993396L (no) 1999-07-09
GB9700504D0 (en) 1997-02-26
US6365599B1 (en) 2002-04-02
PE44499A1 (es) 1999-05-06
AU724990B2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
NO993396D0 (no) Kinolin- ig kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
BR9608651A (pt) Método para o tratamento de hiperplasia prostática benigna com terapia térmica
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
FI931765A7 (fi) Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20002804D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
NO995518L (no) Arylsubstituerte piperaziner brukbare ved behandling av benign prostatisk hyperplasi
PT1054868E (pt) Novas piridino arilpiperazinas substitidas uteis no tratamento de hiperplasia prostatica benigna
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
NO975838D0 (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
AU1036701A (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
ATE222263T1 (de) Prostata-spezifische antigen inhibitore
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU4118900A (en) Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia